Business
KRTL Biotech Advances Global Access to Women’s Health Pharmaceuticals Through Strategic Portfolio Expansion
KRTL Biotech Advances Global Access to Women’s Health Pharmaceuticals Through Strategic Portfolio Expansion.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL\r\nHolding Group Inc. (OTC: KRTL) (\"KRTL Holding\" or the\r\n\"Company\") today announced that its subsidiary, KRTL Biotech, Inc.,\r\nis spotlighting its expanding women’s health pharmaceutical portfolio, which\r\nincludes critical treatments supporting reproductive wellness, maternal care,\r\nand gynecological health.\r\nThe\r\nproducts, developed in collaboration with Industria Químico-Farmacéutica SIGMA\r\nCorp., represent one of the most socially impactful categories within the\r\nCompany’s international pipeline. These therapeutics are widely used across\r\nLatin America in both clinical and over-the-counter settings and are now under\r\nevaluation for global export and U.S. regulatory pathways.\r\n\"Women’s\r\nhealth is foundational to community health,\" said Daniel Bishop, CEO of\r\nKRTL Biotech. \"Our product line addresses real needs — from prenatal\r\nsupport to gynecological infections — using formats that meet international\r\nstandards for safety, accessibility, and affordability.\"\r\nFeatured Women’s Health Products:\r\nThe\r\nportfolio includes prenatal supplements such as iron with folic acid and\r\nmultivitamins, as well as gynecological treatments like clotrimazole (in both\r\ntopical and vaginal formulations) and fluconazole. It also encompasses vaginal\r\nantiseptics, probiotics, and therapeutic products designed to support menstrual\r\ncare and hormonal balance.\r\nThese\r\nformulations are actively distributed across Bolivia through public health\r\nchannels, pharmacies, and hospital procurement. Several of these products are\r\nlisted on national formularies and are already included in maternal and child\r\nhealth programs.\r\nTogether,\r\nthese products empower caregivers, clinics, and women with options for\r\npreventive care, treatment of infections, and nutritional support during\r\npregnancy.\r\n\"At\r\nSIGMA, we have long understood that advancing women’s health is not only a\r\nclinical goal but a social imperative,\" said Patricia Wilstermann, CEO of\r\nSIGMA. \"We’re proud that these products serve both the public and private\r\nsectors in Bolivia — and we’re even more proud to bring this experience to a\r\nglobal platform with KRTL.\"\r\nKRTL\r\nBiotech is currently exploring regulatory alignment for select women’s health\r\nproducts in the U.S. and other regions. Several supplements and ...